A review of breast cancer chemoprevention

Biomedicine and Pharmacotherapy

Volumn 52, Issue 3, 1998, Pages 133-136

  Chang, J C N ^a  

^a NATIONAL UNIVERSITY HOSPITAL   (Singapore)

Author keywords

Breast cancer; Chemoprevention; Tamoxifen

Indexed keywords

RETINOID; TAMOXIFEN;

ARTICLE; BONE MINERAL; BREAST CANCER; CANCER PREVENTION; CARDIOTOXICITY; CHEMOPROPHYLAXIS; CHOLESTEROL BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; GENETIC PREDISPOSITION; GYNECOLOGIC DISEASE; HORMONAL REGULATION; HORMONE SUBSTITUTION; HUMAN; META ANALYSIS; PRIORITY JOURNAL; THROMBOEMBOLISM;

EID: 0032055946     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0753-3322(98)80091-7     Document Type: Article

References (19)

1. 1 Miki Y, Swensen J, Shattuck-Eiden D et al. A strong candidate gene for the breast and ovarian cancer susceptibility gene BRCA1, Science 1994 ; 266 : 66
2. 2 Wooster R, Bignell G, Lancaster J et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995 ; 378 : 789-792
3. 3 Jordan VC. Effect of tamoxifen (ICI 46,474) on initiation and growth of DMBA-induced rat mammary carcinomata. Eur J Cancer 1976 ; 12 : 419-24
4. 4 Schrag D, Kuntz KM, Garber JE et al. Decision analysis-Effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations. New Engl J Med 1997 ; 20 : 1465-71
5. 5 Baum M, Houghton J, Riley D. Results of the Cancer Research Campaign Adjuvant Trial for perioperative cyclophosphamide and long-term tamoxifen in early breast cancer reported at the tenth year of follow-up. Acta Oncol 1992 ; 31(2) : 251-7
6. 6 MacMahon B and Feinlieb M. Breast cancer in relation to nursing and menopausal history. J Natl Cancer Inst 1960 ; 24 : 733-53
7. 7 Powles TJ, Hardy JR, Ashley SE. A pilot trial to evaluate the acute toxicity and feasibility of tamoxifen for prevention of breast cancer. Br J Cancer 1989 ; 60 : 126-31
8. 8 Gail MH, Brintom LA, Byar DP et al. Projecting individualized probabilities of developing breast cancer for white females who are examined annually. J Natl Cancer Inst 1989 ; 81 : 1879-86
9. 9 Love RR, Newcomb PA, Wiebe DA et al. Effects of tamoxifen therapy on lipid and lipoprotein levels in postmenopausal patients with node negative breast cancer. J Natl Cancer Inst 1990 ; 82 : 1327-32
10. 10 McDonald CC, Stewart HJ. Fatal myocardial infarction in the Scottish adjuvant trial. The Scottish Breast Cancer Committee. Br J Cancer 1991 ; 303 : 435-7
11. 11 Jones AL, Powles TJ, Treleaven J et al. Haemostatic changes and thromboembolic risk during tamoxifen therapy in normal women. Br J Cancer 1992 ; 66 : 7744-7
12. 12 Kristensen B, Ejiersten B, Dalgaard P et al. Tamoxifen and bone metabolism in postmenopausal low-risk breast cancer patients : a randomised study. J Clin Oncot 1994 ; 12 : 992-7
13. 13 Powles TJ, Hickish T, Kanis JA et al. The effect of tamoxifen on bone mineral density measured by dual energy x-ray absorptiometry in healthy pre and postmenopausal women. J Clin Oncol 1996 ; 14 : 78-84
14. 14 Fornander T, Hellstrom AC, Moberger B. Descriptive clinicopathologic study of 17 patients with endometrial cancer during or after adjuvant tamoxifen in early breast cancer. J Natl Cancer Inst 1993 ; 85 : 1850-5
15. 15 Kedar RP, Bourne TH, Powles TJ et al. Effects of tamoxifen on the uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial. Lancet 1994 ; 343 : 1318-21
16. 16 Martin EA, Rich JR, White INH et al. 32P-Post labeled DNA adducts in liver obtained from women treated with tamoxifen. Carcinogenesis 1995 ; 16 : 1651
17. 17 Rutqvist LE, Johanson H, Signomklao UI et al. Adjuvant tamoxifen for early stage breast cancer and second primary malignancies. J Natl Cancer Inst 1995 ; 87 : 645-51
18. 18 Pavlidis N, Petris C, Briassoulis E et al. Clear evidence that low-dose tamoxifen treatment can induce ocular toxicity. Cancer 1992 ; 69 : 2961-4
19. 19 Ching CK, Smith PG, Long RG. Tamoxifen-associated hepatocellular damage and agranulocytosis. Lancet 1992 ; 339 : 940